Month: May 2022

Gross Margin Expansion Reflects Continued Demand for Higher Margin Products and Services LOWELL, Mass., May 11, 2022 (GLOBE NEWSWIRE) — CSP Inc. (NASDAQ: CSPI), an award-winning provider of security and packet capture products, managed IT and professional services and technology solutions, reported financial and operating results for the fiscal 2022 second quarter ended March 31, 2022, and provided a business update. Second Quarter Operating Highlights and Recent AchievementsServices revenue grew 21% compared to the year-ago second quarter Backlog as of March 31,2022 was a record $17.3 million, more than doubled compared to $7.8 million on March 31, 2021:$13.0 million of the backlog is in the Technology Solutions (TS) business compared to $7 million year ago $4.3 million of the backlog is in the High-Performance Product (HPP)...

LAS VEGAS, May 11, 2022 (GLOBE NEWSWIRE) — Live Ventures Incorporated (Nasdaq: LIVE), (“Live Ventures” or the “Company”), a diversified holding company, today announced financial results for its fiscal second quarter ended March 31, 2022.  Second Quarter FY 2022 Key Highlights:Revenue of $69.7 million decreased 1.7% as compared with the prior year period Net income of $15.4 million and diluted earnings per share (“EPS”) of $4.84 increased 75.8% and 82.0%, respectively, as compared with the prior year period Adjusted EBITDA¹ of $10.3 million decreased 23.0% as compared with the prior year period ApplianceSmart exited bankruptcy resulting in an $11.4 million gain on bankruptcy settlement Repurchased 65,668 shares of common stock at an average price of $31.72 per share Capital structure simplified as a result of stockholder conversion...

WARREN, N.J., May 11, 2022 (GLOBE NEWSWIRE) — Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the first quarter ended March 31, 2022. “We remain focused on the continued advancement of our late-stage INOpulse® inhaled nitric oxide therapy platform for the treatment of fibrotic interstitial lung disease, or fILD, and pulmonary hypertension associated with sarcoidosis, or PH-Sarc,” said Naseem Amin, M.D., Chairman of Bellerophon’s Board of Directors. “Enrollment is progressing in our pivotal Phase 3 REBUILD study, following the recent moderation of the COVID-19 pandemic. In PH-Sarc, subsequent to the announcement of positive...

Target enrollment achieved in RAPIDe-1, Phase 2 on-demand study of PHVS416 for the treatment of HAE attacks; top-line data anticipated in 4Q22 Enrollment underway in HAE CHAPTER-1, proof-of-concept Phase 2 prophylactic study using PHVS416 for the prevention of HAE attacks; top-line data anticipated in 4Q22 RAPIDe-2, long-term extension on-demand study of PHVS416 for the treatment of HAE attacks, on-track to initiate in 2H22 Continue to execute from a strong financial position with cash and cash equivalents of €194.8 million as of March 31, 2022ZUG, Switzerland, May 11, 2022 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks, building on its deep-seated roots in hereditary angioedema (HAE), today reported financial results...

Received regulatory clearance in Australia to initiate phase 2b trial of lead cancer therapy EVX-01 targeting melanoma Completed recruitment for Phase 1/2a clinical trial for EVX-02 with all patients receiving first dose Announced publication on personalized therapy with EVX-01 in patients with metastatic melanoma in the open-access, peer-reviewed medical science journal OncoImmunology Hosted Key Opinion Leader (KOL) webinar with acclaimed experts on metastatic melanoma and personalized cancer immunotherapies Ended first quarter with cash and cash equivalents of $31.4 million Evaxion will host webcast and conference call today, May 11, at 8:30 am EDTCOPENHAGEN, Denmark, May 11, 2022 (GLOBE NEWSWIRE) — Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development...

Revenue Growth of 30% Year-over-Year in Q1 2022 Conference call to be held today, May 11, 2022, at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, May 11, 2022 (GLOBE NEWSWIRE) — BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today reported first quarter 2022 financial results and provided an operational update. Recent Financial and Operational HighlightsFor the three months ended March 31, 2022, revenues were $8.0 million, a 30% increase as compared to the prior year period. As of March 31, 2022, BrainsWay’s Deep TMS installed base was 790 total systems, a 21% increase from the installed base at the same point in the prior year. As of March 31, 2022, the Company had shipped 337 OCD coils as add-on helmets...